- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers
Join us for this lively discussion with Dr. Joseph Goldberg and Dr. Mauricio Tohen regarding long-acting injectables (LAIs) in the treatment of bipolar I disorder. This moderated session will explore perception, preferences, challenges, and treatment goals for both patients and providers. Discussants will review provider and patient centric perspectives in selecting therapy, plus potential strategies to assess preferences regarding new preventative treatments such as mode of administration, dosing regimen and treatment-related determinants of adherence.
Objectives:
- Describe the challenges to long-term treatment and the importance of management options in patients diagnosed with Bipolar I Disorder (BP-I)
- Discuss the pros and cons of LAIs for patients living with BP-I, from the provider and patient perspective
- Understand strategies to aid in shared decision making between providers and patients when considering LAIs

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai
More

Mauricio Tohen, MD, DrPH, MBA
Chairman, Department of Psychiatry and Behavioral Sciences, Distinguished University Professor, University of New Mexico
More

Michael Aldape, PhD
Senior Medical Science Liaison
Joseph Goldberg, MD and Mauricio Tohen, MD, DrPH, MBA are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Michael Aldape, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
US.CORP.X.23.00219